On September 23, 2026, Brenda Cooperstone, Ph.D., resigned from the Board of Directors and as Chair of the Compensation Committee at Senti Biosciences Holdings, Inc., effective immediately. The company stated that her departure was not due to any disagreements regarding operations or policies. Senti Biosciences is a synthetic biology company focused on developing engineered cell therapies.
